A carregar...
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Alectinib is approved and recommended as the preferred first‐line treatment for patients with anaplastic lymphoma kinase (ALK)‐positive non–small cell lung cancer. The effect of hepatic impairment on the pharmacokinetics (PK) of alectinib was assessed with physiologically based PK modeling prospecti...
Na minha lista:
| Publicado no: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282775/ https://ncbi.nlm.nih.gov/pubmed/30052269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1286 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|